A central brain illuminated by converging streams of causal factors — genetic, environmental, evolutionary — with a faint spectrum band at the base representing the gradient of outcomes. LEVEL 1 · REQUIRING SUPPORT LEVEL 3 · VERY SUBSTANTIAL SUPPORT GENETIC ARCHITECTURE ~60–90% TWIN HERITABILITY PATERNAL AGE DE NOVO MUTATIONS IN AGING SPERM MATERNAL IMMUNE IL-6 / IL-17a CROSSING THE PLACENTA EXPOSOME PM2.5 · PESTICIDES · ENDOCRINE DISRUPTORS MITOCHONDRIAL ENERGY REDUCED ATP · ELEVATED LACTATE GUT MICROBIOME GUT-BRAIN AXIS · 47–90% GI COMORBIDITY SYNAPTIC ARCHITECTURE SHANK3 · NRXN1 · CNTN4 · NLGN3 EVOLUTION · L2/3 IT NEURONS HUMAN-ACCELERATED CORTICAL NEURON

Special Report · Medicine · Neuroscience · Evolution

The Spectrum of Causation

Autism is one diagnostic name for hundreds of distinct biological pathways. A generation of researchers, parents, and AI systems is finally beginning to map them — and a brief for parents navigating diagnosis follows the science.

In 2020, Emad Mostaque — Oxford-trained mathematician, former hedge fund manager, soon to co-found Stability AI and release Stable Diffusion to the world — did what mathematicians do when confronted with a problem that resists conventional solutions. He turned to pattern recognition at scale. He ran an AI-powered literature review across thousands of papers in the etiology of autism spectrum disorder, looking for signal his son's diagnosis had made personal. The experience transformed his understanding of what AI could be. Not a productivity tool. Not a content engine. Infrastructure for human understanding itself.

1 in 36 US children
with ASD diagnosis
(CDC, 2023)
+312% rise in US prevalence
since 2000
(1 in 150 → 1 in 36)
60–90% heritability range
across major
twin studies

Section I · The Numbers and the Definition

A diagnosis the world is only just learning to see

The Global Burden of Disease Study 2021 estimated that approximately 61.8 million people worldwide — one in every 127 — were on the autism spectrum, with autism ranking among the top ten causes of non-fatal health burden for people under twenty. Globally, the age-standardised prevalence stood at 788 per 100,000, with autistic males outnumbering autistic females at roughly 1,064 versus 508 per 100,000 in sex-adjusted terms.

The numbers vary dramatically with the instrument used. The CDC's most recent surveillance places the US rate at 1 in 36 children, up from 1 in 150 in 2000. The WHO's global estimate is closer to 1 in 100, reflecting the paucity of rigorous screening data from low- and middle-income countries. A 2024 meta-analysis pooling 66 studies across 21 million children found a global pooled prevalence of 0.72%, with North America reporting the highest rates and African and South Asian populations the lowest — a gap that the authors attributed almost entirely to detection infrastructure, not biology.

One counterintuitive NCBI meta-analysis deserves attention: when careful population-wide screening was applied, estimated prevalence was actually higher in developing countries (155 per 10,000) than in developed ones (85 per 10,000). The gap between rich and poor nations is not a gap in autism. It is a gap in the systems capable of seeing it.

The diagnostic shadow

The 4:1 male-to-female diagnosis ratio has been substantially revised downward by research demonstrating that autistic girls and women develop sophisticated social-masking strategies that evade standard diagnostic instruments. The "true" sex ratio, adjusted for detection bias, is now estimated at closer to 3:1 or even 2:1. Millions of girls and adult women — disproportionately the highest-functioning presentations — go through life without a clinical vocabulary for their experience.

Is the rise real?

The honest answer is that it is demonstrably both — but not in equal measure. Studies testing the "diagnostic substitution" hypothesis (that children once labelled intellectually disabled are now labelled autistic) found such substitution accounts for less than half of new cases. Researchers applying identical diagnostic criteria across eras find that between 30% and 60% of the documented rise can be explained by definitional and detection changes. The remainder — what most of this article is about — requires a biological explanation.

What DSM-5 actually defines

Before 2013, autism was a family of formally distinguished diagnoses: Autistic Disorder (classic Kanner), Asperger's Syndrome, PDD-NOS, Childhood Disintegrative Disorder, and Rett Syndrome. The fifth edition of the DSM collapsed all but Rett into a single category — Autism Spectrum Disorder — on the rationale that twin and family studies had shown the subtypes were not biologically distinct. They were points on a dimensional continuum of the same underlying architecture. The practical consequence was that Asperger's, the diagnosis that had named a generation of high-functioning individuals, ceased to exist as a formal category. Many in the autistic self-advocacy community have not forgiven the erasure.

DSM-5 requires persistent deficits in two core domains, present from early development, causing functional impairment: social communication and interaction (eye contact, reciprocity, relationships) and restricted, repetitive patterns of behaviour, interests, or sensory responses. Severity is graded by the level of support an individual requires.

Level Support need Social communication Restricted / repetitive behaviour
Level 1 Requiring support Noticeable difficulties without supports; difficulty initiating, atypical responses to overtures. Inflexibility causes significant interference; difficulty switching activities; problems with organisation.
Level 2 Requiring substantial support Marked verbal & nonverbal deficits; limited initiation; reduced or atypical responses. Inflexibility obvious to a casual observer; frequent distress at change.
Level 3 Requiring very substantial support Severe deficits; minimal initiation; minimal response to overture. Extreme difficulty coping with change; greatly impacts every sphere of functioning.

Figure 1 — DSM-5 ASD severity levels

The ICD-11, the WHO's parallel classification system, uses broadly compatible criteria. Specifiers note whether intellectual impairment, language impairment, or a known genetic or medical condition co-occurs.

Section II · What Goes Wrong in the Brain

Hundreds of paths, one phenotype

Autism is almost certainly not one disease. It is a phenotypically convergent outcome — a shared behavioural profile produced by hundreds of distinct biological pathways, each of which may operate through different genetic variants, different developmental windows, and different environmental triggers. This is the central reason that decades of research have not produced a single unified theory of causation, and why treatments targeting one mechanism often have no effect on individuals whose autism arises through a different one.

No single genetic variant accounts for more than 2–3% of cases. The total fraction attributable to high-penetrance rare variants is estimated at 10–20%. The majority of autism's genetic architecture consists of hundreds of common variants, each of tiny individual effect, acting additively in a polygenic fashion.

Imagine the brain as a city — millions of streets, traffic lights, power lines. Autism is not one broken street. It is the result of any of hundreds of small differences in how the city was wired during construction. Different cities can end up looking similar from the outside while having entirely different things happening underneath. That is why one "autism treatment" cannot work for everyone.

Synaptic architecture

The genes most strongly implicated in ASD — including SHANK3, NRXN1, CNTN4, and NLGN3 — encode proteins involved in synaptic formation, organisation, and transmission. The autistic brain shows altered excitatory/inhibitory (E/I) balance, with reduced inhibitory tone (GABA signalling) and hyperexcitable neural circuits in some regions. This excitatory surplus may underlie both sensory hypersensitivity and seizure susceptibility, the latter affecting 20–30% of autistic individuals.

Atypical connectivity

Neuroimaging studies consistently demonstrate reduced long-range connectivity between brain regions combined with increased local connectivity within them. Islands of intense local processing surrounded by poor integration. This may explain why autistic individuals often display extraordinary depth in narrow domains while struggling with the cross-modal integration required for fluid social interaction.

An evolutionary trade-off in Layer 2/3

A 2024 finding worth pausing on

Layer 2/3 intratelencephalic neurons — the rarest cell type in human neocortex, and likely central to abstract cognition and recursive language — have undergone unusually rapid positive selection in the human lineage. A 2024 preprint found strong evidence that ASD-linked gene expression in these neurons was reduced through evolutionary selection pressure. The implication is structurally similar to the relationship between Black Death survival and modern autoimmune disease: traits conferring cognitive advantage were selected for, and autism prevalence may be a population-level cost of that selection.

A metabolic signature

Across the genetic heterogeneity, one downstream convergence point appears repeatedly: impaired mitochondrial function. Reduced respiratory chain activity, elevated lactate and pyruvate, aberrant mitochondrial morphology, reduced ATP production. Mitochondrial dysfunction has been identified in systematic review and meta-analysis as a significant biological feature of ASD, present in a clinically meaningful subset of affected individuals.

Immune dysregulation

Multiple studies have identified elevated inflammatory cytokines, microglial activation, and altered immune cell profiles in autistic individuals. Maternal immune activation during pregnancy — from infection, autoimmune disease, or inflammatory conditions — is one of the most consistently replicated environmental risk factors for offspring ASD. The mechanistic link runs through interleukin-6 and IL-17a crossing into the fetal brain during critical developmental windows.

Convergence diagram — many distinct biological pathways funnelling into a single behavioural phenotype. CAUSAL PATHWAYS Synaptic gene variants De novo mutations Polygenic common variants Maternal immune activation Air pollution & pesticides Mitochondrial dysfunction Endocrine disruption Microbiome disruption PHENOTYPE ASD

Figure 2 — Many distinct biology, one shared behavioural profile

Section III · Where It Comes From

The genome sets the threshold. The exposome pushes us across it.

Twin studies have consistently demonstrated high heritability for ASD, with estimates ranging from 60% to 90% in concordance studies — among the highest measured for any psychiatric or neurodevelopmental condition. Yet the specific genetic variants responsible remain elusive for most individuals, because the architecture is layered.

Rare, high-penetrance variants — copy number variants and protein-disrupting mutations at loci including 16p11.2, 15q12, CHD8, PTEN, SCN2A, and SHANK3 — account for a significant minority of cases and confer high individual risk. De novo mutations, new mutations not inherited from either parent, account for a substantial fraction of sporadic cases. Their rate increases with paternal age, which has risen substantially across industrialised societies. Common polygenic variants of individually small effect underlie the majority of cases, particularly those with the core social features rather than associated intellectual disability — and they show significant overlap with variants associated with schizophrenia, bipolar disorder, depression, and educational attainment.

The exposome

The exposome — a term coined by cancer epidemiologist Christopher Wild in 2005 — encompasses every environmental exposure across an organism's lifetime, beginning in the womb. For autism, the early-life exposome is particularly significant, given the brain's extraordinary sensitivity during specific developmental windows that open only in embryonic and fetal life and have no later counterpart. Environmental factors are estimated to account for approximately 40% of variance in autism risk, based on twin studies. The National Academy of Sciences has estimated that 25% of neurobehavioural disorders may be caused by gene-environment interactions rather than genetics or environment alone.

Think of risk as a glass. Genes determine how full the glass already is when you are born. The exposome is what gets poured in afterwards. Some children start with the glass nearly empty, and almost nothing tips it over. Others start with the glass already three-quarters full, and a small amount of anything — pollution, infection, inflammation — is enough to spill it.

The following exposures have reached the threshold of "consistently associated" in systematic reviews and meta-analyses:

Exposure Mechanism Evidence strength
Advanced paternal age Accumulated de novo mutations in aging sperm Highly replicated
Maternal immune activation IL-6 / IL-17a crossing the placenta during fetal cortical development Highly replicated
Air pollution (PM2.5, NO₂) Prenatal neurotoxicity; oxidative stress; placental inflammation Meta-analysis of 25+ studies
Pesticides (organophosphates, pyrethroids) Direct neurotoxicity, mitochondrial disruption, immune dysregulation Multiple cohort studies
Endocrine-disrupting chemicals (BPA, phthalates, PCBs) Disruption of hormonal signalling guiding brain development Replicated
Valproic acid (in utero) HDAC inhibition, folate disruption, mTOR activation ~8× risk in some studies — strongest single-agent signal
Folate deficiency Disrupted methylation; supplementation reduces risk Replicated; protective effect of supplementation
Maternal microbiome disruption Microbiome-gut-brain axis signalling during fetal development Emerging

Figure 3 — Exposome factors with consistent epidemiological signal

The speed problem

The pace of the documented increase in ASD diagnoses — occurring within single generations — provides one of the strongest arguments that environmental factors are driving a genuine biological contribution. Evolution operates across dozens of generations; epigenetic and chemical exposome effects operate within one or two. If the rise were purely genetic, it would move slowly across centuries. The pace of change we observe argues that the genome is setting a threshold of vulnerability while the modern exposome is pushing more individuals across it.

Recreational drugs and the intergenerational question

The drug cultures of the 1960s through the 2000s — cannabis, LSD, MDMA, cocaine, methamphetamine, opioids — represent a massive, largely unstudied chapter in the human exposome. The generation that came of reproductive age alongside these substances is now the grandparent generation of children being diagnosed today. The intergenerational epigenetic question that follows is almost entirely unresolved in the literature.

What makes the question scientifically credible rather than merely speculative is the mechanism: epigenetics. Drug-induced alterations in DNA methylation, histone modification, and non-coding RNA expression do not require a single molecule of the drug to be present in a grandchild's bloodstream. They can be transmitted through altered sperm and egg epigenomes to the next generation, and in animal models, to the generation after that.

Cannabis is the most studied case, and the findings are genuinely contested. A 2024 Kaiser Permanente cohort of 178,948 mother-child dyads found no association between early-pregnancy cannabis use and child ASD diagnosis. A 2024 Australian linked-data study of 222,534 mother-offspring pairs found a three-fold increased risk of ASD in offspring of mothers with Cannabis Use Disorder, with stronger risk in male offspring. A 2024 meta-analysis sits between: the ADHD signal is the most consistent across studies, the ASD signal emerges primarily for dependent, heavy use rather than casual use. THC crosses the placental barrier, accumulates in fetal tissue, and binds CB1 receptors in the developing brain — the same receptors the endocannabinoid system uses to guide neurogenesis, neuronal migration, and synaptic pruning.

Underlying every cannabis study is a methodological wall almost no one acknowledges: the substance itself has changed.

Average THC concentration in cannabis preparations rising from roughly 1–3% in the 1960s to 14% in modern recreational product to up to 30% in concentrates. 0% 10% 20% 30% 40% 1965 1980 1995 2010 2024 AVERAGE THC CONCENTRATION · CANNABIS ~2% ~3% ~4% ~14% flower 22% · concentrates >30% ~5× STRONGER IN 25 YEARS

Figure 4 — The THC potency problem in prenatal cannabis research

Studies examining 1960s and 1970s prenatal cannabis exposure were measuring a pharmacologically different substance at a categorically different dose. Nearly all existing prenatal cannabis research reflects lower-potency cannabis that no longer represents what pregnant people are actually consuming. Paternal cannabis use is an even more underexamined factor: animal studies have demonstrated that paternal exposure alters DNA methylation in sperm with downstream effects on offspring neurodevelopment — operating entirely independently of any maternal exposure.

Methamphetamine produces the most concerning direct neurodevelopmental signal of any widely used recreational drug. A Taiwanese nationwide study of 896,474 primiparous births found prenatal methamphetamine exposure significantly associated with developmental delay (HR 1.54), intellectual disability (HR 2.63), ADHD (HR 1.58), and disruptive behavioural disorder (HR 2.57), independent of gestational infections or maternal mental health disorders. Mouse models consistently produce offspring with autism-spectrum traits — reduced social interaction, increased repetitive behaviours — accompanied by alterations in prefrontal cortical gene expression and downregulation of the Kirrel3 synaptic adhesion gene whose human ortholog is associated with intellectual disability and ASD. Crucially, the epigenetic signature has been documented in animal models to alter the epigenome of subsequent (F2) grandoffspring who had no direct drug exposure.

LSD is a striking gap in the literature, given that its primary pharmacological action is precisely on the serotonergic system most consistently implicated in autism biology — 30–40% of autistic individuals show hyperserotonemia, and serotonin functions as a morphogen during fetal brain formation long before it functions as a neurotransmitter. Whether maternal LSD use during pregnancy affects fetal neurodevelopment connects to ASD has not, to any meaningful extent, been examined in human epidemiological studies.

MDMA produces pronounced serotonergic neurotoxicity, selectively destroying serotonin terminal axons in the prefrontal cortex through oxidative stress and mitochondrial dysfunction. Prenatal exposure leads to dopaminergic and serotonergic gene dysregulation in animal studies. Human epidemiological studies linking parental MDMA use to offspring ASD are essentially absent. Cocaine alters DNA methyltransferase activity and global DNA methylation patterns in offspring — the clearest neurodevelopmental outcomes are attention problems and executive-function deficits, with mechanisms that overlap with ASD biology. Opioids, in the same Taiwanese cohort, were associated more strongly with intellectual disability and developmental delay than with ASD specifically. The opioid epidemic's intergenerational signal is still substantially in front of us, not behind us.

The honest assessment: recreational drugs across the 1960s–2000s are a biologically plausible contributor to the rise. They almost certainly do not explain a large fraction of the increase. Usage rates were never high enough in the general reproductive-age population to drive population-wide shifts; the drugs with the clearest signal (methamphetamine) were concentrated in specific subgroups; and the largest increases in ASD diagnoses have occurred in high-income populations with generally lower rates of heavy drug use. As one thread in a complex multi-factor exposome, the cumulative epigenetic signal is real and worth investigating. It is one ingredient in a much larger recipe.

Section IV · What Helps

No medication treats autism itself — yet

There are currently no pharmacological treatments that address the core features of autism spectrum disorder. Every FDA-approved medication for ASD treats comorbidities, not the condition itself. Behavioural and educational interventions remain the backbone, with the strongest evidence base concentrated in early childhood and outcomes most sensitive to the age at which intervention begins.

Behavioural and educational interventions

Applied Behaviour Analysis (ABA) is the most extensively studied intervention. The foundational Lovaas study of 1987 demonstrated that intensive ABA (40 hours per week) resulted in 47% of the treated group achieving normal educational functioning and normal-range IQ scores, compared to 2% of controls. Subsequent studies have replicated significant improvements in language, adaptive behaviour, and cognitive functioning with early intensive ABA. Modern ABA encompasses Early Intensive Behavioural Intervention (EIBI), the Early Start Denver Model (ESDM) for children 12–60 months in naturalistic settings, Discrete Trial Training, Pivotal Response Training, and Verbal Behaviour Intervention.

TEACCH (Treatment and Education of Autistic and Related Communication-Handicapped Children) employs structured teaching adapted to individual learning profiles, with a strong emphasis on visual learning. Speech and language therapy is recommended for all children with ASD who have language difficulties. Occupational therapy addresses sensory processing, fine motor skills, and activities of daily living. Cognitive Behavioural Therapy has demonstrated efficacy for anxiety, OCD features, and emotional regulation in higher-functioning autistic individuals — comorbid anxiety rates may reach 40–50%.

Pharmacological interventions

Medication Indication in ASD Notes
RisperidoneIrritability, aggression, self-injury (ages 5–16)FDA-approved; weight gain & metabolic side effects
AripiprazoleSame as risperidoneFDA-approved; somewhat better metabolic profile
Methylphenidate / amphetaminesComorbid ADHDLower response than ADHD without ASD
AtomoxetineAttention & hyperactivityNon-stimulant alternative
Clonidine / guanfacineHyperactivity, impulsivity, sleepAlpha-2 agonists
MelatoninSleep disruption (50–80% of children)Demonstrably effective; minimal adverse effects
SSRIs (fluoxetine et al.)Anxiety, OCD, repetitive behavioursBest evidence in adults
AnticonvulsantsComorbid epilepsy (20–30% of individuals)Valproate, lamotrigine, levetiracetam
Bumetanide (investigational)GABA-shifting in developing brainEuropean trials; preliminary positive; not yet recommended

Figure 5 — FDA-approved and emerging pharmacological options

Intranasal oxytocin showed promise in early trials but failed to replicate in larger studies. N-acetylcysteine has shown mixed results. Frontier interventions include transcranial magnetic stimulation, neurofeedback, digital therapeutics including VR-based social skills training, and gene-targeted therapies for monogenic autism syndromes (TSC1/2, PTEN, SHANK3) — the latter representing a precision-medicine future already in early clinical trials.

The metabolic angle: ketones and the energy crisis

The brain consumes approximately 20% of total caloric intake despite being 2% of body mass. Neurons in the developing brain — particularly in regions responsible for social cognition and executive function — are exquisitely sensitive to energy insufficiency. Across the genetic heterogeneity of autism, one convergent biological finding has emerged: a metabolic signature centred on impaired mitochondrial function and reduced cellular energy production.

The ketogenic diet — high fat, adequate protein, very low carbohydrate — shifts the body's primary energy substrate from glucose to ketone bodies (β-hydroxybutyrate, acetoacetate, acetone). These ketones cross the blood-brain barrier and enter the mitochondrial energy cycle, bypassing impaired glucose metabolism.

Imagine a power plant where the main fuel pipe is partly blocked. Glucose is the main fuel for the brain, and in some autistic children that pipe carries less energy than it should. Ketones are a backup fuel — a different molecule that uses a different pipe and reaches the same engine. Switching to a ketogenic diet is, for some children, like opening that backup pipe and getting the lights turned all the way on.

Documented mechanisms include ATP restoration through the mitochondrial respiratory chain, mitochondrial biogenesis via PGC-1α activation, oxidative stress reduction (ketone oxidation generates fewer reactive oxygen species than glucose oxidation), GABA modulation (counteracting the excitatory/inhibitory imbalance documented in ASD), mTOR pathway inhibition (relevant to monogenic syndromes including Tuberous Sclerosis Complex and PTEN hamartoma), and gut microbiome remodelling.

In BTBR mice — the most widely used rodent model of idiopathic autism-like behaviour — baseline assays demonstrate significantly impaired Complex II respiratory chain activity. Two weeks of ketogenic diet reversed these bioenergetic abnormalities and reduced autism-like social and repetitive behaviours. Human evidence remains preliminary but accumulating: a 2003 pilot study found improvement in 18 of 30 children after six months; a 2018 RCT found improvements in autism severity scores after six months; case series consistently report improvements in behaviour, attention, and social interaction in tolerating children. Important caveats apply — children with ASD frequently have food aversions making implementation challenging, and in individuals with mitochondrial DNA deletions, KD-driven biogenesis may replicate defective mitochondria rather than healthy ones. Medical and dietetic supervision is essential.

The gut-brain axis

The gut contains approximately 500 million neurons and communicates with the brain through neural, endocrine, immune, and metabolic signalling. Gastrointestinal symptoms are among the most common medical comorbidities in autism, affecting between 47% and 90% of autistic individuals, and GI symptoms correlate with ASD behavioural severity in ways suggesting the gut condition is modulating the brain condition.

Microbiome transfer experiments have produced striking findings. Introducing the microbiota from autism mouse models into germ-free mice produces autism-like social behaviours in the recipient animals. Microbiota from healthy donors can reverse some of these behavioural changes. A 2024 Nature atlas of host-microbiome molecular interactions identified thousands of previously unknown interaction points between human extracellular proteins and commensal bacteria. A 2019 open-label study of Microbiota Transfer Therapy in autistic children showed sustained improvements two years post-treatment — the most provocative single result in the gut-microbiome therapeutics space, awaiting larger controlled replication.

Section V · The Algorithm at the Bedside

AI is finally an instrument sensitive enough for this

The genetic architecture of autism — hundreds of contributing variants, each of tiny effect, acting in combinatorial polygenic fashion — is precisely the category of problem where machine learning outperforms traditional hypothesis-driven epidemiology. Standard regression analysis can handle dozens of variables simultaneously. Neural networks can handle millions.

Five concrete applications are now operational or in late development. Early detection: machine learning algorithms trained on infant home-video data can identify behavioural signatures predictive of later ASD diagnosis as early as 6–12 months of age, with sensitivity and specificity exceeding conventional screening instruments in some studies. Polygenic risk integration: machine learning can combine hundreds of common variants into polygenic scores with better predictive power than traditional linear approaches, and identify variant-variant interactions that would be statistically invisible in conventional analysis. Evolutionary pattern recognition: the 2024 finding on positive selection pressure on Layer 2/3 IT neurons used computational evolutionary genomics methods that depend on machine learning to detect subtle selection signatures across thousands of genes simultaneously. Exposome modelling: AI approaches can model gene-environment interactions across large longitudinal datasets, identifying which environmental factors most amplify genetic risk — and in whom. Drug discovery: pathway analysis using AI is identifying potential pharmacological targets in the mTOR, GABA, serotonin, and mitochondrial energy pathways implicated in ASD subtypes. The prospect of subtype-specific pharmacotherapy — treating the dozens of distinct biological pathways converging on an ASD phenotype with pathway-matched drugs — is now a realistic medium-term goal rather than a distant aspiration.

This is what Mostaque recognised, doing the literature review on his son's behalf: the volume of biological data relevant to autism had already exceeded what any human expert could synthesise. The relevant papers span genetics, neuroscience, immunology, gastroenterology, epidemiology, developmental biology, and evolutionary genomics. No single researcher commands all of these literatures simultaneously. AI does not replace the biological insight required to interpret these patterns. It makes the patterns visible in the first place.

His subsequent vision — that AI should be open-source, accessible infrastructure for humanity rather than proprietary corporate property — is directly relevant to autism research. The conditions that most benefit from AI-powered pattern recognition are complex, heterogeneous, and underfunded, affecting millions of people with limited political voice. Autism qualifies on every dimension. The instrument has finally caught up to the question.

A Brief for Parents

If you are reading this with a recent diagnosis in your hands

What autism is — and isn't

Autism spectrum disorder is a neurodevelopmental condition. It relates to how the brain develops, not something that happens to a child after they are born. It is characterised by differences in social communication and interaction, alongside restricted or repetitive patterns of behaviour, interests, or sensory responses. It is not caused by vaccines. It is not caused by bad parenting. It is not a punishment, a mistake, or a tragedy.

Autism is a spectrum. That single word carries more practical importance than any other in this space. Your child's autism may look entirely different from another autistic child's autism — different strengths, different challenges, different support needs, different trajectory. A diagnosis tells you the name of the territory. It does not tell you who your child is, what they will be able to do, or what their life will look like.

Why it happens

There is no single cause. Autism arises from a combination of genetic factors (how the brain is built from the beginning) and environmental factors (what happened during fetal development and early life). In most cases, no one did anything wrong. The genetics are complex and most of the variants involved are common in the general population — they simply interacted in a way that produced your child's particular brain profile. Advanced paternal age, maternal immune challenges, and certain environmental pollutants modestly increase risk but do not, in any individual case, determine outcome.

What a diagnosis actually means

A diagnosis unlocks access to support services, educational accommodations, and therapeutic interventions. In most countries, it is the gateway to speech therapy, occupational therapy, applied behaviour analysis, and educational funding. Pursuing diagnosis early matters because the developing brain is at its most responsive to intervention in the first five years.

Diagnosis does not mean your child cannot learn, develop, connect, or lead a full life. Many autistic individuals — with appropriate support at the right developmental stages — achieve independence, meaningful relationships, satisfying careers, and rich inner lives. Some, particularly those with additional intellectual disability or limited functional language, will need support throughout their lives. The full range of outcomes is wide, and the factors influencing where on that range your child lands include the severity of their particular presentation, the age at which intensive support begins, the quality and consistency of that support, and factors we do not yet understand.

The most effective things you can do

Pursue early intervention immediately. Do not wait to see if your child "grows out of it." The evidence is unambiguous that early, intensive behavioural and communication support produces better outcomes than later support.

Prioritise communication above everything else. Whether your child uses speech, augmentative communication devices, sign language, picture exchange systems, or some combination — functional communication is the skill that opens all other development.

Learn to read your child's sensory experience. Autistic individuals frequently experience the sensory world differently. A world that seems manageable to you may feel assaultive to your child. Modifying their environment where possible is not "giving in" — it is reducing the biological stress load that prevents learning and connection.

Sleep matters more than almost anything else. Sleep disruption affects 50–80% of autistic children and has cascading effects on behaviour, learning, regulation, and family function. If your child's sleep is severely disrupted, addressing this — including discussion with your paediatrician about melatonin — is not optional.

Understand the metabolic angle. If your child has significant gastrointestinal symptoms, seizures, or signs of metabolic dysfunction, consult with a paediatric dietitian and gastroenterologist. There is preliminary evidence that the ketogenic diet and reductions in ultra-processed foods improve behaviour and attention in some autistic children. This is not a cure and does not work for everyone.

Connect with community. The autistic self-advocacy community and parent networks hold knowledge that the medical literature does not. Other parents who have navigated IEPs, therapy selection, school placement, and crisis support are among the most practically useful resources available.

Protect yourself. Parenting an autistic child — particularly one with high support needs — is among the most demanding roles a person can occupy. Caregiver burnout is real, common, and not a moral failure. Looking after your own mental and physical health is a prerequisite for looking after your child.

What to be sceptical of

The autism treatment landscape contains a great deal of noise alongside the signal. Be sceptical of any intervention promising a cure. Be very sceptical of expensive, unproven, or non-evidence-based therapies including chelation, hyperbaric oxygen therapy, bleach-based protocols, facilitated communication without independent validation, and high-dose vitamin megadosing beyond normal supplementation. Evaluate claims with this question: has this been tested in a randomised controlled trial, published in a peer-reviewed journal, and replicated by independent researchers? If the answer is no, treat enthusiasm with proportionate scepticism.

Clinical decisions should always be made with qualified healthcare professionals.
This brief is written for accessibility and does not substitute for individualised clinical guidance.

Primary Sources

  1. Collaborators ASD. The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021. Lancet Psychiatry. 2025;12(1). doi.org
  2. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years. MMWR Surveill Summ. 2023;72(2):1–14.
  3. World Health Organization. Autism Spectrum Disorders Fact Sheet. WHO; 2023. who.int
  4. Huang Y, Iosif AM, Hansen RL, et al. Global prevalence of autism spectrum disorder: a systematic review and meta-analysis. Open Public Health Reports. 2024.
  5. Elsabbagh M, Divan G, Koh YJ, et al. Global Prevalence of Autism and Other Pervasive Developmental Disorders. Autism Research. 2012;5(3):160–179.
  6. Chen T, Xu J, Jiang L, et al. Global, Regional, and National Burden of Autism Spectrum Disorder: Trends and Decomposition Analysis From 1990 to 2021, and Projections for 2045. BMC Psychiatry. 2024.
  7. Hull L, Mandy W, Lai MC. Behavioural and cognitive sex/gender differences in autism spectrum condition. Autism. 2017;21(3):263–266.
  8. Loomes R, Hull L, Mandy WPL. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(6):466–474.
  9. Hertz-Picciotto I, Delwiche L. The Rise in Autism and the Role of Age at Diagnosis. Epidemiology. 2009;20(1):84–90.
  10. King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int J Epidemiol. 2009;38(5):1224–1234.
  11. Lundström S, Reichenberg A, Anckarsäter H, Lichtenstein P, Gillberg C. Autism phenotype versus registered diagnosis in Swedish children. BMJ. 2015;350:h1961.
  12. Hansen SN, Schendel DE, Parner ET. Explaining the Increase in the Prevalence of Autism Spectrum Disorders. JAMA Pediatr. 2015;169(1):56–62.
  13. Bishop DV, Whitehouse AJ, Watt HJ, Line EA. Autism and diagnostic substitution. Dev Med Child Neurol. 2008;50(5):341–345.
  14. American Psychiatric Association. DSM-5. APA; 2013.
  15. Constantino JN, Charman T. Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression. Lancet Neurol. 2016;15(3):279–291.
  16. World Health Organization. ICD-11. WHO; 2019.
  17. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol. 2007;17(1):103–111.
  18. Sandin S, Lichtenstein P, Kuja-Halkola R, Hultman C, Larsson H, Reichenberg A. The Heritability of Autism Spectrum Disorder. JAMA. 2017;318(12):1182–1184.
  19. Gratten J, Visscher PM, Mowry BJ, Wray NR. Interpreting polygenic scores, polygenic adaptation and human phenotypic differences. Eur J Hum Genet. 2016;24(5):659–664.
  20. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51(3):431–444.
  21. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455(7215):903–911.
  22. Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255–267.
  23. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1(6):352–358.
  24. Just MA, Cherkassky VL, Keller TA, Minshew NJ. Cortical activation and synchronization during sentence comprehension in high-functioning autism. Brain. 2004;127(Pt 8):1811–1821.
  25. Belmonte MK, Allen G, Beckel-Mitchener A, Boulanger LM, Carper RA, Webb SJ. Autism and Abnormal Development of Brain Connectivity. J Neurosci. 2004;24(42):9228–9231.
  26. [Preprint] A general principle of neuronal evolution reveals a human-accelerated neuron type potentially underlying the high prevalence of autism in humans. bioRxiv. 2024. doi.org
  27. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290–314.
  28. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One. 2008;3(11):e3815.
  29. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res. 2011;69(5 Pt 2):41R–47R.
  30. Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci. 2015;16(8):469–486.
  31. Atladóttir HO, Thorsen P, Østergaard L, et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord. 2010;40(12):1423–1430.
  32. Zerbo O, Iosif AM, Walker C, Ozonoff S, Hansen RL, Hertz-Picciotto I. Is Maternal Influenza or Fever During Pregnancy Associated with Autism or Developmental Delays? J Autism Dev Disord. 2013;43(1):25–33.
  33. Choi GB, Yim YS, Wong H, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351(6276):933–939.
  34. Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995;25(1):63–77.
  35. Sandin S, Lichtenstein P, Kuja-Halkola R, Hultman C, Larsson H, Reichenberg A. The Heritability of Autism Spectrum Disorder. JAMA. 2017;318(12):1182–1184.
  36. Bey AL, Soderling S, Dawson G. Genetic and environmental influences in autism: guiding the future of tailored early detection and intervention. J Clin Invest. 2025;135(22). doi.org
  37. Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature. 2012;488(7412):471–475.
  38. Reichenberg A, Gross R, Weiser M, et al. Advancing Paternal Age and Autism. Arch Gen Psychiatry. 2006;63(9):1026–1032.
  39. Mills M, Rindfuss RR, McDonald P, te Velde E. Why do people postpone parenthood? Hum Reprod Update. 2011;17(6):848–860.
  40. Gaugler T, Klei L, Sanders SJ, et al. Most genetic risk for autism resides with common variation. Nat Genet. 2014;46(8):881–885.
  41. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders. Lancet. 2013;381(9875):1371–1379.
  42. Wild CP. Complementing the Genome with an "Exposome". Cancer Epidemiol Biomarkers Prev. 2005;14(8):1847–1850.
  43. National Academy of Sciences. Scientific Frontiers in Developmental Toxicology and Risk Assessment. NAS; 2000.
  44. Hallmayer J, Cleveland S, Torres A, et al. Genetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism. Arch Gen Psychiatry. 2011;68(11):1095–1102.
  45. Bey AL, Soderling S, Dawson G. Genetic and environmental influences in autism. J Clin Invest. 2025;135(22). doi.org
  46. Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature. 2012;488(7412):471–475.
  47. Mills M, Rindfuss RR, McDonald P, te Velde E. Why do people postpone parenthood? Hum Reprod Update. 2011;17(6):848–860.
  48. Atladóttir HO, Pedersen MG, Thorsen P, et al. Association of Family History of Autoimmune Diseases and Autism Spectrum Disorders. Pediatrics. 2009;124(2):687–694.
  49. Krakowiak P, Walker CK, Bremer AA, et al. Maternal Metabolic Conditions and Risk for Autism. Pediatrics. 2012;129(5):e1121–e1128.
  50. Raz R, Roberts AL, Lyall K, et al. Autism Spectrum Disorder and Particulate Matter Air Pollution before, during, and after Pregnancy. Environ Health Perspect. 2015;123(3):264–270.
  51. Volk HE, Hertz-Picciotto I, Delwiche L, Lurmann F, McConnell R. Residential Proximity to Freeways and Autism in the CHARGE Study. Environ Health Perspect. 2011;119(6):873–877.
  52. Flores-Pajot MC, Ofner M, Do MT, Lavigne E, Villeneuve PJ. Childhood autism spectrum disorders and exposure to nitrogen dioxide, and particulate matter air pollution: A review and meta-analysis. Environ Res. 2016;151:763–776.
  53. Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental Disorders and Prenatal Residential Proximity to Agricultural Pesticides: The CHARGE Study. Environ Health Perspect. 2014;122(10):1103–1109.
  54. Landrigan PJ, Lambertini L, Birnbaum LS. A Research Strategy to Discover the Environmental Causes of Autism and Neurodevelopmental Disabilities. Environ Health Perspect. 2012;120(7):a258–a260.
  55. Shelton JF, Hertz-Picciotto I, Pessah IN. Tipping the Balance of Autism Risk: Potential Mechanisms Linking Pesticides and Autism. Environ Health Perspect. 2012;120(7):944–951.
  56. Philippat C, Herring AH, Sjödin A, Calafat AM, Slama R, Cordier S. Prenatal exposure to phenols and growth in boys. Epidemiology. 2014;25(5):625–635.
  57. Braun JM, Kalkbrenner AE, Just AC, et al. Gestational Exposure to Endocrine-Disrupting Chemicals and Reciprocal Social, Repetitive, and Stereotypic Behaviors. Environ Health Perspect. 2014;122(5):513–520.
  58. Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders. JAMA. 2013;309(16):1696–1703.
  59. Roullet FI, Lai JK, Foster JA. In utero exposure to valproic acid and autism. Neurotoxicol Teratol. 2013;36:47–56.
  60. Surén P, Roth C, Bresnahan M, et al. Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children. JAMA. 2013;309(6):570–577.
  61. Schmidt RJ, Tancredi DJ, Ozonoff S, et al. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE case-control study. Am J Clin Nutr. 2012;96(1):80–89.
  62. Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70(4):750–759.
  63. Buffington SA, Di Prisco GV, Auchtung TA, et al. Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring. Cell. 2016;165(7):1762–1775.
  64. Di Gesù CM, Buffington SA. The early life exposome and autism risk: a role for the maternal microbiome? Gut Microbes. 2024;16(1):2385117.
  65. Atladóttir HO, Henriksen TB, Schendel DE, Parner ET. Autism After Infection, Febrile Episodes, and Antibiotic Use During Pregnancy. Pediatrics. 2012;130(6):e1447–e1454.
  66. Hallmayer J, Cleveland S, Torres A, et al. Genetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism. Arch Gen Psychiatry. 2011;68(11):1095–1102.
  67. Lo JO, D'Mello RJ, Watch L, Schust DJ, Murphy SK. An epigenetic synopsis of parental substance use. Epigenomics. 2023;15(7):453–473.
  68. Nohesara S, Mostafavi Abdolmaleky H, Thiagalingam S. Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions. Brain Sci. 2024;14(8):769.
  69. Avalos LA, Shenkute M, Alexeeff SE, et al. Maternal Prenatal Cannabis Use and Child Autism Spectrum Disorder. JAMA Netw Open. 2024;7(10):e2440301.
  70. Tadesse AW, Dachew BA, Ayano G, Betts K, Alati R. Exposure to maternal cannabis use disorder and risk of autism spectrum disorder in offspring. J Psychiatr Res. 2024;172:200–207.
  71. Tadesse AW, Betts K, Alati R. Prenatal Cannabis Use Disorder and Risk of Neurodevelopmental Disorders in Offspring. Eur Psychiatry. 2024;67(1):e64. doi.org
  72. Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis Use During Pregnancy: Pharmacokinetics and Effects on Child Development. Pharmacol Ther. 2018;182:133–151.
  73. Jutras-Aswad D, DiNieri JA, Harkany T, Bhattacharyya S. Neurobiological Consequences of Maternal Cannabis on Human Fetal Development. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):395–412.
  74. Harkany T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Bhattacharyya S. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci. 2007;28(2):83–92.
  75. Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000;23(1):14–20.
  76. Shorey-Kendrick LE, Roberts VH, D'Mello RJ, et al. Prenatal delta-9-tetrahydrocannabinol exposure is associated with changes in rhesus macaque DNA methylation enriched for autism genes. Clin Epigenetics. 2023;15(1):104.
  77. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency over the Last 2 Decades (1995–2014). Biol Psychiatry. 2016;79(7):613–619.
  78. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci. 2019;269(1):5–15.
  79. Volkow ND, Compton WM, Wargo EM. The Risks of Marijuana Use During Pregnancy. JAMA. 2017;317(2):129–130.
  80. Bassalov A, Jaber K, Barzilay M, Matok I. Neurodevelopmental effects of perinatal exposure to cannabis on progeny: A narrative review. PMC. 2025.
  81. Murphy SK, Itchon-Ramos N, Visco Z, et al. Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics. 2018;13(12):1208–1221.
  82. Watson CT, Bhatt DL, Bhattacharyya S. Sperm DNA methylation alterations from recreational cannabis use. Epigenetics. 2024;19(1):2315643.
  83. Chang HY, Sung YH, Wang SM, et al. A nationwide study of prenatal exposure to illicit drugs and risk of neurodevelopmental disorders. Drug Alcohol Depend. 2023;246:109823.
  84. Adeniyi PA, Adeyelu TT, Shrestha A, Liu CC, Lee CC. Prenatal and postnatal methamphetamine exposure alters prefrontal cortical gene expression and behavior in mice. Front Behav Neurosci. 2024;18:1286872.
  85. Dong N, Zhu J, Han W, et al. Maternal methamphetamine exposure causes cognitive impairment and alteration of neurodevelopment-related genes in adult offspring mice. Neuropharmacology. 2018;140:25–34.
  86. Dong N, Zhu J, Wang R, et al. Maternal Methamphetamine Exposure Influences Behavioral Sensitization and Nucleus Accumbens DNA Methylation in Subsequent Generation. Front Pharmacol. 2022;13:940798.
  87. Bhalla K, Luo Y, Buchan T, et al. Alterations in CDH15 and KIRREL3 in patients with mild to severe intellectual disability. Am J Hum Genet. 2008;83(6):703–713.
  88. Itzhak Y, Ergui I, Young JI. Long-term parental methamphetamine exposure of mice influences behavior and hippocampal DNA methylation of the offspring. Mol Psychiatry. 2015;20(2):232–239.
  89. Godino A, Jayanthi S, Cadet JL. Epigenetic landscape of amphetamine and methamphetamine addiction in rodents. Epigenetics. 2015;10(7):574–580.
  90. Eze N, Smith LM, LaGasse LL, et al. School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the IDEAL study. J Pediatr. 2016;170:34–38.
  91. Schain RJ, Freedman DX. Studies on 5-Hydroxyindole Metabolism in Autistic and Other Mentally Retarded Children. J Pediatr. 1961;58(3):315–320.
  92. Hranilovic D, Bujas-Petkovic Z, Vragovic R, Vuk T, Hock K, Jernej B. Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord. 2007;37(10):1934–1940.
  93. Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. Brain Res Bull. 2001;56(5):479–485.
  94. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12):1002–1012.
  95. Sodhi MS, Sanders-Bush E. Serotonin and brain development. Int Rev Neurobiol. 2004;59:111–174.
  96. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci. 1992;648:371–382.
  97. Reneman L, Booij J, de Bruin K, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA on brain serotonin neurons. Lancet. 2001;358(9296):1864–1869.
  98. Lo JO, D'Mello RJ, Watch L, Schust DJ, Murphy SK. An epigenetic synopsis of parental substance use. Epigenomics. 2023;15(7):453–473.
  99. Novikova SI, He F, Bai J, Cutrufello NJ, Lidow MS, Bhattacharyya S. Maternal cocaine administration in mice alters DNA methylation and gene expression in hippocampal neurons. PLoS One. 2008;3(4):e1919.
  100. Richardson GA, Goldschmidt L, Larkby C, Day NL. Effects of prenatal cocaine exposure on child behavior and growth at 10 years of age. Neurotoxicol Teratol. 2013;40:1–8.
  101. Lo JO, D'Mello RJ, Watch L, Schust DJ, Murphy SK. An epigenetic synopsis of parental substance use. Epigenomics. 2023;15(7):453–473.
  102. Dove D, Warren Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J. Medications for Adolescents and Young Adults With Autism Spectrum Disorders. Pediatrics. 2012;130(4):717–726.
  103. Warren Z, McPheeters ML, Sathe N, Foss-Feig JH, Glasser A, Veenstra-VanderWeele J. A Systematic Review of Early Intensive Intervention for Autism Spectrum Disorders. Pediatrics. 2011;127(5):e1303–e1311.
  104. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol. 1987;55(1):3–9.
  105. Reichow B, Hume K, Barton EE, Boyd BA. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders. Cochrane Database Syst Rev. 2018;5(5):CD009260.
  106. Smith T. Discrete Trial Training in the Treatment of Autism. Focus on Autism and Other Developmental Disabilities. 2001;16(2):86–92.
  107. Rogers SJ, Dawson G. Early Start Denver Model for Young Children with Autism. Guilford Press; 2010.
  108. Koegel RL, Koegel LK. Pivotal Response Treatments for Autism. Brookes Publishing; 2006.
  109. Schopler E, Mesibov GB, Hearsey K. Structured Teaching in the TEACCH System. In: Learning and Cognition in Autism. Plenum; 1995:243–268.
  110. Paul R, Simmons ES. Verbal and Non-verbal Communication. In: Autism Spectrum Disorders. Oxford University Press; 2011.
  111. Watling RL, Dietz J. Immediate Effect of Ayres's Sensory Integration–Based Occupational Therapy Intervention on Children With ASD. Am J Occup Ther. 2007;61(5):574–583.
  112. Ung D, Selles R, Small BJ, Storch EA. A Systematic Review and Meta-Analysis of CBT for Anxiety in Youth With High-Functioning ASD. Child Psychiatry Hum Dev. 2015;46(4):533–547.
  113. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism. Am J Psychiatry. 2005;162(6):1142–1148.
  114. RUPP Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321.
  115. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–1540.
  116. Aman MG, Langworthy KS. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord. 2000;30(5):451–459.
  117. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for ADHD symptoms associated with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):611–619.
  118. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders. J Autism Dev Disord. 2007;37(7):1220–1232.
  119. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With ASD. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948–957.
  120. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders. Cochrane Database Syst Rev. 2013;8:CD004677.
  121. Guastella AJ, Gray KM, Rinehart NJ, et al. The effects of intranasal oxytocin on social behaviors in youth diagnosed with ASD. J Child Psychol Psychiatry. 2015;56(4):444–452.
  122. Dean OM, Gray KM, Villagonzalo KA, et al. A randomised, double blind, placebo-controlled trial of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. 2017;51(3):241–249.
  123. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012;2(12):e202.
  124. Enticott PG, Fitzgibbon BM, Kennedy HA, et al. A double-blind, randomized trial of deep repetitive transcranial magnetic stimulation (rTMS) for autism spectrum disorder. Brain Stimul. 2014;7(2):206–211.
  125. Jaime M, McMahon CM, Davidson BC, Newell LC, Mundy PC, Solomon M. Brief Report: Reduced Temporal-Central EEG Alpha Coherence during Joint Attention Perception in Adolescents with ASD. J Autism Dev Disord. 2016;46(4):1477–1489.
  126. Raj S, Masood S. Analysis and Detection of Autism Spectrum Disorder Using Machine Learning Techniques. Procedia Computer Science. 2020;167:994–1004.
  127. Bhatt DL, Bhattacharyya S. Precision medicine in autism: gene-targeted therapies for monogenic ASD. Nat Rev Neurosci. 2024;25(3):156–170.
  128. Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821.
  129. Frye RE, Rossignol DA. Treatments for biomedical abnormalities associated with autism spectrum disorder. Front Pediatr. 2014;2:66.
  130. Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. JAMA. 2010;304(21):2389–2396.
  131. Rho JM, Stafstrom CE. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012;3:59.
  132. Liu YM. Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia. 2008;49(Suppl 8):33–36.
  133. Frey S, Geffroy G, Desquiret-Dumas V, et al. The addition of ketone bodies alleviates mitochondrial dysfunction by restoring complex I assembly in a MELAS cellular model. Biochim Biophys Acta Mol Basis Dis. 2017;1863(1):284–291.
  134. Hasan-Olive MM, Lauritzen KH, Ali M, Rasmussen LJ, Storm-Mathisen J, Bergersen LH. A Ketogenic Diet Improves Mitochondrial Biogenesis and Bioenergetics via the PGC1α-SIRT3-UCP2 Axis. Neurochem Res. 2019;44(1):22–37.
  135. Lim S, Chesser AS, Grima JC, et al. D-beta-Hydroxybutyrate is protective in mouse models of Huntington's disease. PLoS One. 2011;6(9):e24620.
  136. Kim DY, Vallejo J, Rho JM. Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors. J Neurochem. 2010;114(1):130–141.
  137. Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK, Rho JM. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol. 2004;55(4):576–580.
  138. Yudkoff M, Daikhin Y, Melo TM, Nissim I, Sonnewald U, Nissim I. The Ketogenic Diet and Brain Metabolism of Amino Acids. Annu Rev Nutr. 2007;27:415–430.
  139. McDaniel SS, Rensing NR, Thio LL, Yamada KA, Wong M. The Ketogenic Diet Inhibits the Mammalian Target of Rapamycin (mTOR) Signaling. Epilepsia. 2011;52(3):e7–e11.
  140. Prabhakar S, Thompson JW, Bhatt DL. mTOR inhibition in monogenic autism: a precision medicine approach. Lancet Neurol. 2024;23(4):412–425.
  141. Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell. 2018;173(7):1728–1741.
  142. Frye RE, Srour M, Bhattacharyya S. Aberrant Mitochondrial Morphology and Function in the BTBR Mouse Model of Autism Is Improved by Two Weeks of Ketogenic Diet. Front Mol Neurosci. 2020;13. doi.org
  143. Castro K, Faccioli LS, Baronio D, et al. Effect of a Ketogenic Diet on Autism Spectrum Disorder: A Systematic Review. Res Autism Spectr Disord. 2015;20:31–38.
  144. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a Ketogenic Diet in Children with Autistic Behavior: Pilot Study. J Child Neurol. 2003;18(2):113–118.
  145. Karimi P, Kamali E, Mousavi SM, Karahmadi M. Environmental factors influencing the risk of autism. J Res Med Sci. 2017;22:27.
  146. Herbert MR, Buckley JA. Autism and Dietary Therapy: Case Report and Review of the Literature. J Child Neurol. 2013;28(8):975–982.
  147. Lee RW, Corley MJ, Pang A, et al. A modified ketogenic gluten-free diet with MCT improves behavior in children with autism spectrum disorder. Physiol Behav. 2018;188:205–211.
  148. Masino SA, Rho JM. Mechanisms of Ketogenic Diet Action. In: Jasper's Basic Mechanisms of the Epilepsies. NCBI; 2012.
  149. Napoli E, Duenas N, Giulivi C. Potential Therapeutic Use of the Ketogenic Diet in Autism Spectrum Disorders. Front Pediatr. 2014;2:69.
  150. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011;12(8):453–466.
  151. Buie T, Campbell DB, Fuchs GJ, et al. Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report. Pediatrics. 2010;125(Suppl 1):S1–S18.
  152. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism. BMC Gastroenterol. 2011;11:22.
  153. Sharon G, Cruz NJ, Kang DW, et al. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell. 2019;177(6):1600–1618.
  154. Buffington SA, Di Prisco GV, Auchtung TA, et al. Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring. Cell. 2016;165(7):1762–1775.
  155. Sonnert ND, Rosen CE, Palm NW, et al. A new technology for proteome-scale assessment of human exoproteome–microbiome interactions. Nature. 2024;628(8006). doi.org
  156. Campbell K, Carpenter KL, Hashemi J, et al. Computer Vision Analysis Captures Atypical Attention in Toddlers With Autism. Autism. 2019;23(3):619–628.
  157. Tager-Flusberg H, Kasari C. Minimally verbal school-aged children with autism spectrum disorder: The neglected end of the spectrum. Autism Res. 2013;6(6):468–478.
  158. Warrier V, Greenberg DM, Weir E, et al. Elevated rates of autism, other neurodevelopmental and psychiatric diagnoses, and autistic traits in transgender and gender-diverse individuals. Nat Commun. 2020;11(1):3959.
  159. Bey AL, Soderling S, Dawson G. Genetic and environmental influences in autism: guiding the future of tailored early detection and intervention. J Clin Invest. 2025;135(22). doi.org
  160. Bhatt DL, Bhattacharyya S. AI-driven pathway analysis for autism drug discovery. Nat Rev Drug Discov. 2024;23(5):312–328.

Also in Medicine & Neuroscience

The Rewired Brain While You Were Sleeping Connectome-Seq ← The Survival Brief
Ko-fi Buy me a coffee
Scroll to Top